玻璃体腔注射贝伐珠单抗在增生性玻璃体视网膜病变视网膜脱离患者玻璃体切除术中的疗效:前瞻性研究的Meta分析
该Meta分析检索PubMed、Embase和Cochrane对照试验中心注册库至2016年10月,纳入3项前瞻性研究共120只增生性玻璃体视网膜病变相关视网膜脱离眼,评估玻璃体切除术中玻璃体腔注射贝伐珠单抗的疗效。结果显示贝伐珠单抗组与非贝伐珠单抗组在最佳矫正视力、视网膜再脱离率及玻璃体切除至再脱离间隔上均无临床或统计学重要差异(P>0.05)。作者结论为贝伐珠单抗未降低再脱离率或改善视力,需更大样本更长随访的研究。
要点
- 纳入了3项前瞻性研究共120只PVR相关视网膜脱离眼。
- 贝伐珠单抗组与非贝伐珠单抗组的最佳矫正视力和视网膜再脱离率均无临床或统计学重要差异(P>0.05)。
- 贝伐珠单抗未影响玻璃体切除至视网膜再脱离的间隔(P>0.05)。
核心结论
- 基于现有证据,PVR相关视网膜脱离患者玻璃体切除术中玻璃体腔注射贝伐珠单抗未降低视网膜再脱离率或改善视力。
- 需要设计更好、样本量更大、随访时间更长的研究来得出关于获益与危害的有效结论。
- 未来可考虑评估抗血管内皮生长因子治疗对较轻PVR亚型或无PVR但被认为PVR高风险眼的手术结局的影响。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane对照试验中心注册库自最早收录至2016年10月的研究。
- 遵循PRISMA指南,使用Stata 12.0软件分析,采用加权均数差、相对危险度及其95%置信区间评估关联强度。
- 最终纳入3项前瞻性研究,共120只PVR相关视网膜脱离眼。
主要发现
- 最佳矫正视力在贝伐珠单抗组与非贝伐珠单抗组之间无临床或统计学重要差异(P>0.05)。
- 视网膜再脱离率在贝伐珠单抗组与非贝伐珠单抗组之间无临床或统计学重要差异(P>0.05)。
- 贝伐珠单抗未影响玻璃体切除至视网膜再脱离的间隔(P>0.05)。
局限性
- 需要设计更好、样本量更大、随访时间更长的研究来得出关于获益与危害的有效结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effect of intravitreal injection of bevacizumab in vitrectomy for patients with proliferative vitreoretinopathy (PVR)-related retinal detachment. METHODS: The PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from their earliest entries through October, 2016, to identify the studies that had evaluated the effects of intravitreal injection of bevacizumab in vitrectomy for eyes with PVR-related retinal detachment. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. The relevant data were analyzed using Stata 12.0 software. The weighted mean difference, relative risk, and their 95% confidence intervals were used to assess the strength of the association. RESULTS: The authors' search yielded 133 records from which 3 studies that have examined the effects of intravitreal injection of bevacizumab (120 eyes with PVR-related retinal detachment) were included for review and analysis. Their meta-analyses showed that neither the best-corrected visual acuity nor retinal redetachment rate showed any clinically or statistically important difference between the nonbevacizumab and bevacizumab groups (P > 0.05). In addition, bevacizumab did not influence the interval between vitrectomy and retinal redetachment (P > 0.05). CONCLUSION: Based on the available evidence, intravitreal injection of bevacizumab in vitrectomy for patients with PVR-related retinal detachment did not decrease retinal redetachment rate or improve visual acuity. Better-designed studies with larger simple sizes and longer follow-up periods are required to reach valid conclusions regarding benefits and harms. Moreover, evaluation of anti-vascular endothelial growth factor therapy on surgical outcomes in eyes with milder subtypes of PVR or no PVR, but deemed at high risk of PVR, may be worthy of future consideration.
引用
- Zhao XY, Xia S, Wang EQ, et al. EFFICACY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN VITRECTOMY FOR PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT: A Meta-analysis of Prospective Studies. Retina. 2018. PMID: 28272285. doi:10.1097/IAE.0000000000001584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。